BNTC vs EDIT
BNTC: Benitec Biopharma is a biotechnology company advancing a proprietary 'silence and replace' gene therapy platform to address rare genetic disorders like OPMD. EDIT: A gene editing pioneer leveraging CRISPR technology to develop in vivo, one-time therapies for serious genetic diseases.
Side-by-side fundamentals
| Metric | BNTC | EDIT | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $8.75 | $2.84 | |
| Market cap | $305M | $436M | |
| Net margin | -23528.8% | -395.0% | EDIT higher |
| Operating margin | -23044.1% | -394.9% | EDIT higher |
| ROE | -25.7% | -586.6% | BNTC higher |
| ROA | -24.9% | -85.8% | BNTC higher |
| Debt / equity as of 2026-09-03 | 0.00 | 0.53 | BNTC lower |
| Revenue growth (YoY) as of 2026-09-03 | n/a | +20.8% | |
| Revenue CAGR (3y) SEC XBRL | -93.0% | +27.1% | EDIT higher |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-09-03 | 0.81 | 2.23 | |
| 1-year return as of 2026-10-08 close | -37.9% | -31.6% | EDIT higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.